LONG-TERM SAFETY AND EFFICACY OF ADALIMUMAB FROM THE PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH NAIL AND SKIN PSORIASIS

被引：0
|
作者：
Crowley, Jeff [1 ]
Gisondi, Paolo [2 ]
Geng, Ziqian [3 ]
Servin, Ofelia Reyes [3 ]
机构：
[1] Bakersfield Dermatol, Bakersfield, CA USA
[2] Univ Verona, Verona, Italy
[3] AbbVie Inc, N Chicago, IL USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P055
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of adalimumab from the phase 3 randomized placebo-controlled trial in patients with nail and skin psoriasis
    Crowley, Jeff
    Gisondi, Paolo
    Geng, Ziqian
    Servin, Ofelia Reyes
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB181 - AB181
  • [2] Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
    Elewski, Boni E.
    Okun, Martin M.
    Papp, Kim
    Baker, Christopher S.
    Crowley, Jeffrey J.
    Guillet, Gerard
    Sundaram, Murali
    Poulin, Yves
    Gu, Yihua
    Geng, Ziqian
    Williams, David A.
    Rich, Phoebe A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (01) : 90 - +
  • [3] Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a Phase-3, randomized, placebo-controlled trial
    Elewski, B. E.
    Rich, P. A.
    Okun, M. M.
    Papp, K.
    Baker, C. S.
    Crowley, J. J.
    Guillet, G.
    Gu, Y.
    Geng, Z.
    Sundaram, M.
    Williams, D. A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 65 - 65
  • [4] Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
    Elewski, B. E.
    Baker, C. S.
    Crowley, J. J.
    Poulin, Y.
    Okun, M. M.
    Calimlim, B.
    Geng, Z.
    Servin, O. Reyes
    Rich, P. A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) : 2168 - 2178
  • [5] Adalimumab for nail psoriasis: Efficacy and safety from the open-label extension of a phase-3, randomized, placebo-controlled trial
    Gottlieb, Alice B.
    Elewski, Boni E.
    Okun, Martin M.
    Bagel, Jerry
    Poulin, Yves
    Gu, Yihua
    Williams, David A.
    Valdecantos, Wendell C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB33 - AB33
  • [6] Efficacy of adalimumab in nail psoriasis by baseline subgroups, and overall safety from first 26 weeks of a phase 3, randomized, placebo-controlled trial
    Rich, Phoebe A.
    Baker, Christopher S.
    Valenzuela, Fernando
    Rey, Maria P.
    Geng, Ziqian
    Gu, Yihua
    Servin, Ofelia Reyes
    Poulin, Yves
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB200 - AB200
  • [7] PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS
    Elewski, B. E.
    Rich, P. A.
    Behrens, F.
    Guillet, G.
    Geng, Z.
    Servin, O. Reyes
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1319 - 1320
  • [8] PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS
    Elewski, Boni E.
    Rich, Pheobe A.
    Behrens, Frank
    Guillet, Gerard
    Geng, Ziqian
    Servin, Ofelia Reyes
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 26 - 27
  • [9] Primary efficacy and safety of adalimumab in nail psoriasis from the first 26weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis
    Elewski, Boni E.
    Rich, Phoebe A.
    Behrens, Frank
    Guillet, Gerard
    Geng, Ziqian
    Servin, Ofelia Reyes
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB204 - AB204
  • [10] Efficacy of adalimumab in nail psoriasis by history of psoriatic arthritis and overall safety from final, open-label 26 weeks of a phase 3, randomized, placebo-controlled trial
    Elewski, Boni E.
    Armstrong, April W.
    Coates, Laura C.
    Rubel, Diana
    Rashid, Javed
    Geng, Ziqian
    Gu, Yihua
    Servin, Ofelia Reyes
    Behrens, Frank
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB201 - AB201
12345